Evolus (EOLS) has a profit margin of -9.56%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
Evolus (EOLS) currently reports a profit margin of -9.56% as of September 2026. That compares with -20.52% in the prior-year period — up 53.4% year over year. That is below the Healthcare sector average of 17.63%. Use the charts on this page to explore Evolus's profit margin history and peer comparisons.
Evolus's profit margin increased from -20.52% to -9.56% — a 53.4% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Evolus's profit margin of -9.56% is lower than the Healthcare sector average of 17.63%. That is roughly 154.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Evolus's current -9.56% should be judged against Healthcare norms (sector average: 17.63%) and against EOLS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -9.56%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for Evolus, and consider following EOLS for alerts when major investors trade the stock.